Cour Pharmaceuticals Names Danielle Appelhans as New CEO

Cour Pharmaceuticals has declared that Danielle Appelhans, the company's current CEO, will follow John J. Puisis as president and CEO. September 1st will mark the start of the new policy. Puisis will stay on the board of directors of the business and advise Cour until the end of the year. Appelhans has been added to Cour's board of directors as well. Puisis established Cour in 2015 and has guided the clinical-stage biotech company through many collaborations, clinical trials, and INDs. In January, Cour completed a $105 million fundraising round to promote its products and advance its initiatives in the field of autoimmune treatments. Puisis formerly held the positions of CEO and co-founder of Third Wave Technologies and Tolera Therapeutics.

Appelhans has overseen R&D, technological development, clinical operations, quality, technical operations, and corporate strategy since joining Cour as COO last year. She is excited to continue building on Cour's recent successes by diversifying its business and moving clinical projects to critical phases, all with the ultimate goal of providing patients with novel, life-altering therapies. Appelhans has been a member of the Generation Bio board of directors and was the former CEO of Rubius Therapeutics. She has worked with Novartis, Sandoz, McKinsey & Company, and Eli Lilly and Company in a variety of capacities. Puisis has faith in Appelhans' capacity to steer Cour through the upcoming stages of development and expansion as well as in her vision for the company's future.